May 22, 2020
Global Cancer Antibody Drug Conjugate Market: A US$13 Billion Opportunity
Apr 27, 2020
Graft Versus Host Disease (GvHD) Pipeline Guide, H1 2020
Apr 02, 2020
Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality
Feb 27, 2020
Hodgkin Lymphoma Treatment Market Forecasts to 2025 with Alkem Labs, Amneal Pharma, Baxter Int'l, Biogen, BMS, Roche, Incyte Corp, Merck & Co, Seattle Genetics, and Teva Pharma Industries Dominating
Feb 27, 2020
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
Feb 18, 2020
Global ADC Linker & Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience
Feb 10, 2020
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 02, 2019
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Nov 06, 2019
Global Antibody Drug Conjugates Market Report 2019-2030
Nov 04, 2019
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Oct 22, 2019
Clinical Trials for Acute Myeloid Leukemia (AML) Drug Therapy Advancing With Encouraging Results
Sep 28, 2019
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
Sep 16, 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Aug 29, 2019
The Antibody Drug Conjugates Market is Projected to be Worth More Than USD 15 Billion by 2030, Growing at a CAGR of Over 20%, Claims Roots Analysis
Jul 16, 2019
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jun 28, 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Jun 14, 2019
World Cancer Immunotherapy Market Report 2019 - Outcome Potential / Fast Tracking / Funding / Technology Environment / Target Solutions
Jun 03, 2019
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer